Targeting a specific protein to reduce inflammation and aid recovery after viral pneumonia
Project 3: Targeting linear ubiquitination to attenuate inflammation and promote repair after viral pneumonia
This study is looking at how a protein called LUBAC affects inflammation and healing in the lungs of people with acute respiratory distress syndrome (ARDS) after viral infections like COVID-19, with the hope of finding new ways to help them recover better.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10910892 on NIH RePORTER |
What this research studies
This research investigates how a protein complex called LUBAC affects inflammation and lung repair in patients suffering from acute respiratory distress syndrome (ARDS) following viral infections like COVID-19. By understanding the role of LUBAC in regulating inflammatory responses, the research aims to identify new therapeutic strategies that could enhance recovery from lung injuries. The approach involves studying the mechanisms of inflammation resolution and lung repair, particularly focusing on the activity of a transcription factor known as NF-κB. The ultimate goal is to develop interventions that can improve patient outcomes in those experiencing severe respiratory complications.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with ARDS, particularly those who have experienced severe respiratory distress due to viral infections like COVID-19.
Not a fit: Patients with ARDS caused by non-viral factors or those who are not experiencing significant inflammation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve recovery and reduce complications for patients with ARDS caused by viral infections.
How similar studies have performed: Previous research has shown promising results in targeting inflammatory pathways for improving outcomes in ARDS, suggesting that this approach could be effective.
Where this research is happening
Chicago, United States
- Northwestern University at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Budinger, Gr Scott — Northwestern University at Chicago
- Study coordinator: Budinger, Gr Scott
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.